|
|
|
|
| LEADER |
02462nmm a2200325 u 4500 |
| 001 |
EB000624042 |
| 003 |
EBX01000000000000000477124 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9781461512851
|
| 100 |
1 |
|
|a Hawthorne, M. Frederick
|e [editor]
|
| 245 |
0 |
0 |
|a Frontiers in Neutron Capture Therapy
|h Elektronische Ressource
|c edited by M. Frederick Hawthorne, Kenneth Shelly, Richard J. Wiersema
|
| 250 |
|
|
|a 1st ed. 2001
|
| 260 |
|
|
|a New York, NY
|b Springer US
|c 2001, 2001
|
| 300 |
|
|
|a LV, 1467 p
|b online resource
|
| 505 |
0 |
|
|a Introductory Overviews -- Clinical Experiences -- Treatment Planning and Clinical Considerations -- Reactor Neutron Sources and Facilities -- Accelerators and other Neutron Sources -- Dosimetry -- Fast Neutron Studies -- Chemistry and Synthesis -- Imaging and Analysis of Nuclides -- Pharmacology and Compound Evaluation -- Tissue Targeting -- Preclinical Dosimetry -- Preclinical Radiobiology -- Future Directions and Emerging Applications -- Author Index, Vol. 1 -- Keyword Index, Vol. 1 -- Participants List -- Author Index, Vol. 2 -- Keyword Index, Vol. 2
|
| 653 |
|
|
|a Radiology
|
| 653 |
|
|
|a Cancer
|
| 653 |
|
|
|a Biophysics
|
| 653 |
|
|
|a Cancer Biology
|
| 653 |
|
|
|a Oncology
|
| 700 |
1 |
|
|a Shelly, Kenneth
|e [editor]
|
| 700 |
1 |
|
|a Wiersema, Richard J.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 028 |
5 |
0 |
|a 10.1007/978-1-4615-1285-1
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-4615-1285-1?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.994
|
| 520 |
|
|
|a Frontiers in Neutron Capture Therapy contains current research results originally presented at the Eighth International Symposium on Neutron Capture Therapy for Cancer in La Jolla, CA. This comprehensive collection of peer-reviewed manuscripts is showcased in two volumes covering all aspects of the development of this multidisciplinary approach to cancer therapy. Volume I of this work includes clinical results and current progress in treatment planning, neutron sources and dosimetry, while Volume II presents the synthesis, pharmacology and tissue-targeting design of boron compounds, including work on preclinical dosimetry and radiobiology. Intended for researchers and clinicians involved with or interested in new modes of cancer therapy, this volume will also serve as a useful guideline for scientists, students, and practitioners in the field
|